In addition, miR-200a was downregulated in breast cancer and re-expression of miR-200a released Nrf2 from Keap1 via triggering Keap1 mRNA degradation, leading to nuclear translocation of Nrf2 and subsequent transcription of target genes [115]. The gene discussed is KEAP1; the disease is breast cancer.